From: Clinical evaluation of intensity-modulated radiotherapy for locally advanced pancreatic cancer
Factors | Number of patients | 1-year LRPFS (%) | p-value | 1-year OS (%) | p-value |
---|---|---|---|---|---|
Age (years) | |||||
< 66 | 58 | 52.6 | 0.039 | 64.7 | 0.11 |
≥66 | 49 | 81.0 | 85.5 | ||
Gender | |||||
Male | 45 | 71.9 | 0.88 | 77.4 | 0.67 |
Female | 62 | 59.5 | 72.0 | ||
Tumor size | |||||
< 3 cm | 64 | 65.0 | 0.11 | 77.7 | 0.047 |
≥3 cm | 43 | 66.7 | 69.3 | ||
Radiation modality | |||||
3DCRT | 80 | 63.2 | 0.035 | 68.2 | 0.037 |
IMRT | 27 | 73.1 | 92.3 | ||
PS | |||||
0 | 52 | 65.2 | 0.55 | 78.3 | 0.053 |
1–2 | 55 | 66.2 | 70.5 | ||
Pretreatment CA19–9 (U/ml) | |||||
< 300 | 64 | 76.7 | 0.0026 | 82.2 | 0.010 |
≥300 | 43 | 50.0 | 62.8 | ||
Tumor location | |||||
Body/Tail | 50 | 69.4 | 0.24 | 76.0 | 0.21 |
Head/Neck | 57 | 62.3 | 72.8 |